Global equity markets have been rocked recently as fears of rising interest rates and tightening monetary possible make their way into the minds of the street.
Keep Reading →
June 26 - News
Dividend stocks are hard to come by in the biotech space.
Keep Reading →
June 26 - News
A double-digit drop for Amgen, Inc. (NASDAQ:AMGN) stock over the past couple of months has likely left a bad taste in the mouths of shareholders.
Keep Reading →
June 25 - News
Which biotech companies are the best-run? That could be a difficult question to answer, since there are many perspectives on what constitutes a well-run company.
Keep Reading →
June 24 - News
Almost all retirement investment strategies advocate generating a steady income from dividend payments from well-established, safe stocks.
Keep Reading →
June 18 - News
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Keep Reading →
June 17 - Stock Analysis
It's understandably very tempting for people with inside information to trade biotech stocks.
Keep Reading →
June 17 - News
Biotech stocks can provide astronomical returns but also depressing losses.
Keep Reading →
June 14 - News
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
June 13 - News
Celgene Corporation (NASDAQ:CELG) shares have soared more than 46% so far in 2013.
Keep Reading →
June 12 - News
Economic theory suggests that insiders should generally only buy the company’s stock if they are particularly confident in the business’s prospects, preferring to diversify...
Keep Reading →
June 12 - Hedge Funds
Celgene Corporation (NASDAQ:CELG)’s Abraxane is primarily used to treat breast and lung cancer.
Keep Reading →
June 10 - News
The biotechnology industry is one of the favorite industries for investing in up-and-coming companies.
Keep Reading →
June 6 - News
As I noted 12 weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
June 6 - News
Celgene Corporation (NASDAQ:CELG) announced good news today about its blockbuster drug Revlimid. Did the stock jump as a result? Nope. Shares actually fell by more than 4%.
Keep Reading →
June 6 - News
Celgene Corporation (NASDAQ:CELG) was one of several companies presenting at the American Society of Clinical Oncology, or ASCO, annual meeting in Chicago this week.
Keep Reading →
June 4 - News
Editor's Note: The initial article refers to Abraxane's prostate cancer trials. That is incorrect, Abraxane has priority review for pancreatic cancer.
Keep Reading →
June 4 - News
The Food and Drug Administration stays busy with approvals, recommendations, and reviews.
Keep Reading →
June 3 - News
Over the past three months, we've taken a deep dive into the 12 cancer types most likely to be diagnosed in the U.S.
Keep Reading →
June 3 - News
You have plenty of choices of where to invest your portfolio.
Keep Reading →
May 31 - News
Having heard about and invested enough in large-cap pharma, I believe it is time to consider funding smaller firms in the sector.
Keep Reading →
May 30 - News
A recent report by EvaluatePharma claims that sales of orphan drugs -- ones that target rare diseases -- will grow at twice the rate of the overall prescription market.
Keep Reading →
May 30 - News
Currently, a majority of pharma companies are facing the issue of generic competition.
Keep Reading →
May 28 - News
You want to invest in biotech. You hear about all the monstrous pops and mini-fortunes that are built overnight.
Keep Reading →
May 28 - News
Celgene Corporation (NASDAQ:CELG) was in 44 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
May 24 - News
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Keep Reading →
May 24 - News
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
Keep Reading →
May 23 - News
Investors emphasize the "bio" in biotech a great deal. We look at how much patients' health improved in clinical trials.
Keep Reading →
May 16 - News
As we enter the heart of second-quarter earnings reports, I can't help but point out that the majority we've covered over the past year have been better than expected.
Keep Reading →
May 13 - News
Bio stocks can be a gamble.
Keep Reading →
May 1 - News
Rising biotech stars Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), and Gilead Sciences, Inc.
Keep Reading →
April 29 - News
I don't know about you, but I'm pretty stoked for the NFL draft this Thursday.
Keep Reading →
April 22 - News
On Tuesday, Amgen, Inc. (NASDAQ:AMGN) will release its latest quarterly results.
Keep Reading →
April 21 - News
If you haven't noticed, it's earnings season once again! Believe it or not, there are times when earnings reports slow down in frequency, but this is certainly not one of those...
Keep Reading →
April 21 - News
Shares of Amgen, Inc. (NASDAQ:AMGN) have returned over 65% in the past year; 109% if dividends are included. The S&P 500 has returned just over 13%.
Keep Reading →
April 18 - News
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Keep Reading →
April 16 - Stock Analysis
The biotechnology sector can be a land of immense spoils and incredible heartbreak.
Keep Reading →
April 7 - News
With the tax deadline less than two weeks away, thinking about ways to reduce your tax liability and/or eliminate your future taxes by opening or contributing to an Individual...
Keep Reading →
April 3 - News
It was generally a great quarter for U.S.
Keep Reading →
April 1 - News
Few big biotech firms have been as successful recently as Celgene Corporation (NASDAQ:CELG).
Keep Reading →
March 26 - News
Big pharma loves Obamacare, right? After all, the main lobbying group for big pharma, the Pharmaceutical Researchers and Manufacturers of America, or PhRMA, spent $150 million...
Keep Reading →
March 23 - News
With the Nasdaq Biotechnology Index hitting record highs, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about whether we're in...
Keep Reading →
March 22 - News
As I noted three weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
March 20 - News
To most traders, hedge funds are viewed as slow, old investment vehicles of the past.
Keep Reading →
March 19 - Hedge Funds
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) may be the perfect biotech company for your speculative portfolio.
Keep Reading →
March 19 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 19 - News
Buying big pharma stocks isn't the only way you can invest in today's best-selling drugs without taking a gamble on a small, risky biotech.
Keep Reading →
March 18 - News
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S.
Keep Reading →
March 12 - News
The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co.
Keep Reading →
March 12 - News